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Abstract
Background: Severe toxicity to 5-fluorouracil (5-FU) based chemotherapy in gastrointestinal cancer has been
associated with constitutional genetic alterations of the dihydropyrimidine dehydrogenase gene (DPYD).
Methods: In this study, we evaluated DPYD promoter methylation through quantitative methylation-specific PCR
and screened DPYD for large intragenic rearrangements in peripheral blood from 45 patients with gastrointestinal
cancers who developed severe 5-FU toxicity. DPYD promoter methylation was also assessed in tumor tissue from
29 patients
Results: Two cases with the IVS14+1G > A exon 14 skipping mutation (c.1905+1G > A), and one case carrying the
1845 G > T missense mutation (c.1845G > T) in the DPYD gene were identified. However, DPYD promoter
methylation and large DPYD intragenic rearrangements were absent in all cases analyzed.
Conclusions: Our results indicate that DPYD promoter methylation and large intragenic rearrangements do not
contribute significantly to the development of 5-FU severe toxicity in gastrointestinal cancer patients, supporting
the need for additional studies on the mechanisms underlying genetic susceptibility to severe 5-FU toxicity.
Background
The fluoropyrimidine 5-fluorouracil (5-FU) is broadly
used in the treatment of a wide range of gastrointestinal
cancers[1]. 5-FU is an analogue of uracil with a fluorine
atom at the C-5 position replacing hydrogen, which
enters the cell using the same transport machinery as
the uracil nucleotide[2]. The mechanism of 5-FU cyto-
toxicity has been ascribed to the inhibition of thymi-
dylate synthase (TYMS) and misincorporation of
fluoronucleotides into RNA and DNA [1,3]. The rate-
limiting enzyme in 5-FU catabolism is dihydropyrimi-
dine dehydrogenase (DPD), which converts 5-FU to
dihydrofluorouracil. More than 80% of administered
5-FU is normally catabolized primarily in the liver,
where DPD is abundantly expressed[1].
The types of toxicity associated with 5-FU are predo-
minantly myelosuppression, diarrhea, mucositis, and
hand-foot syndrome[4,5]. The mechanism of 5-FU cyto-
toxicity may depend on genetic and clinical factors.
Female gender and mode of administration in bolus are
linked to increased toxicity[6]. In 5-FU bolus schedules,
the incorporation of fluorouridine triphosphate into
RNA appears to be the most important mechanism of
action, whereas when the infusion time is prolonged,
inhibition of TYMS becomes more important resulting
in lower toxicity[7].
The expression levels of DPD and TYMS vary among
individuals and may be related to different toxicity pro-
files. These might also be potentially important as prog-
nostic factors and predictive markers of response to
5-FU[8,9]. However, no reliable molecular marker of
sensitivity, resistance, or toxicity to 5-FU has been vali-
dated until now[10]. However, partial or complete DPD
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detected in 3% to 5% of the general population, which
has been associated with severe and potentially lethal
toxicity following 5-FU administration[11].
The dihydropyrimidine dehydrogenase gene (DPYD),
which codes for DPD, is present as a single copy gene
on chromosome 1p22 and consists of 23 exons.
Although more than 50 gene alterations have been char-
acterized during the past decade[12], the majority of
them represents missense or intronic variants with
unknown biological and clinical significance[12,13].
Indeed, only a limited number of patients are carriers of
allelic variants (including the most prevalent exon 14
skipping mutation, IVS14+1 G>A )t h a ts i g n i f i c a n t l y
affect DPD catalytic activity[14]. Recently, large intra-
genic rearrangements of DPYD and a new interstitial
deletion [del(1)(p13.3p21.3)] were found in some DPD
deficient patients[15].
Nevertheless, the genetic variants reported thus far do
not account for most of the DPD deficiency cases. Thus,
epigenetic de-regulation of DPYD was hypothesized as
an alternative mechanism for reduced DPD activity. In
this setting, Noguchi and co-workers found that DPD
activity was controlled at the transcriptional level by
promoter methylation and thus aberrant methylation
might affect the sensitivity to 5-FU in hepatocarcinoma
cell lines[16]. Subsequently, Ezzeldin et al. assessed DPD
activity and DPYD promoter methylation status in a
small series of clinical samples (n = 15) from normal
individuals and cancer patients [17]. DPYD promoter
methylation was detected in peripheral bloods samples
from all (five) DPD-deficient volunteers and in three out
of five DPD-deficient cancer patients with a previous
history of 5-FU toxicity. Interestingly, no evidence of
methylation was detected in samples from five volun-
teers with normal DPD activity[17]. Finally, methylation
of DPYD promoter region of RKO colorectal cancer cell
line was shown to be associated with decreased gene
expression[18].
We sought to characterize the DPYD promoter
methylation status and the presence of large intragenic
rearrangements in a series of gastro-intestinal (GI) can-
cer patients to determine whether these might constitute
alternative mechanisms for DPD deficiency and a cause
of severe 5-FU toxicity.
Methods
Study design
The primary objective of this cross-sectional study was
to analyze the methylation status of DPYD promoter
region in GI patients who developed severe 5-FU toxi-
city. The secondary objective was the analysis of large
intragenic rearrangements of DPYD.
Patient selection and Clinical evaluation
Forty-five patients with esophageal, gastric or colorectal
cancer (Table 1) who had developed severe toxicity fol-
lowing chemotherapy regimens based on 5-FU and had
been tested for DPYD exon 14 mutations (including the
exon 14 skipping mutation IVS14+1G > A) by direct
sequencing analysis at the Portuguese Oncology Insti-
tute - Porto, Portugal, from January 1994 through
December 2008. All the patients were enrolled in this
study, following informed consent. These studies were
approved by the respective institutional review board
(Comissão de Ética do IPO-Porto).
Data on patient demographics (gender and age),
ECOG, tumor anatomical site, TNM staging, 5-FU-
based chemotherapy scheme, mode of administration
and toxicity profile were assessed by detailed hospital
chart review for each case (Table 1). This study included
45 patients (24 women and 21 men). The median age
was 56 years (ranging from 34 to 76 years) without dif-
ferences across gender (p = 0.432). The combination of
5-FU with cisplatinum was given in 23 cases (51.1%),
which were all esophageal or gastric cancer patients. In
the 22 colorectal patients, 5-FU was given in conjunc-
tion with levamisole in 2 cases, combined with folinic
acid in 12 cases. FolFOx was administered in 6 cases
and FolFIri in 2 cases.
Table 1 Clinical and pathological characteristics of
patient population
n (%)
No. of patients 45 (100)
Gender; Median age
(Min - Max), yrs
Female 24 (53.3); 54
(34 - 76)
Male 21 (46.7); 61
(35 - 75)
ECOG 0 20 (44.4)
≥ 1 25 (55.6)
Tumor Location Esophageal 4 (8.9)
Gastric 19 (42.2)
Colorectal 22 (48.9)
TNM Stage II 3 (6.7)
III 12 (26.7)
IV 30 (66.7)
Treatment Purpose Adjuvant 14 (31.1)
Palliative 31 (68.9)
Chemotherapy Scheme 5-FU/Cisplatinum 23 (51.1)
Other* 22 (48.9)
5FU
Mode of Administration
Bolus alone 15 (33.3)
Bolus + CI
# 8 (17.8)
Continuous infusion 22 (48.9)
*5-FU/LV or 5-FU/FA or FolFOx or FolFIri;
#Continous Infusion
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fied according to the Common Terminology Criteria for
Adverse Events (CTCAE) v4.0[19]. Accordingly, toxicity
grades 3 or 4 were considered severe. Patients developed
the following manifestations of toxicity grade 3 or 4
during chemotherapy with 5-FU (Figure 1): mucositis
(24 cases, 53%), anorexia (21 cases, 47%), neutropenia
(14 cases, 31%), anemia (6 cases, 13%), nausea/vomiting
(6 cases, 13%), diarrhea (5 cases, 11%), thrombocytope-
nia (4 cases, 9%) and hand-foot syndrome (3 cases, 7%).
The clinicopathological characteristics and toxicity
profile of three carriers of DPYD mutations identified in
this study are provided in Table 2.
Sample collection and tissue processing
A peripheral blood sample was obtained for all patients,
and in 29 of these, a tumor-representative formalin-
fixed, paraffin-embedded tissue block (biopsy or surgical
specimen before chemotherapy) was available. Routine
histopathological evaluation, comprising diagnosis, grad-
ing and pathological staging according to WHO[20] was
performed in all cases. Serial sections were obtained
from each of the representative tissue block and an
expert pathologist delineated their highest proportion of
malignant cells. Colorectal carcinoma cell line RKO
from American Type Tissue Collection (ATTC, USA)
was used as a positive control for methylation analysis
(this cell line is methylated at the DPYD promoter).
RKO cells were grown in ATCC-formulated Dulbecco’s
Modified Eagle Medium.
DNA extraction, quantification and modification
DNA was extracted from all available samples (RKO cell
line, peripheral blood and microdissected tumor tissue)
with phenol-chloroform method[21] and quantified
using Nanodrop™ ND1000 microspectrophotometer
(NanoDrop, USA). Genomic DNA extracted from per-
ipheral blood, cell line and microdissected tumor was
submitted to sodium bisulfite conversion using a pre-
viously described method [22-24]. Briefly, 1 μgo fg e n o -
mic DNA from each sample were used for the chemical
treatment. Bisulfite-modified DNA was purified using a
vacuum manifold and a Wizard DNA Clean-up System
[Promega Corp., WI, USA ], treated again with sodium
hydroxide, precipitated with ethanol, eluted in 60 μlo f
water and stored at -80°C.
Real-time, quantitative, methylation-specific PCR
T h ec h e m i c a l l ym o d i f i e dD N Af r o mt h eR K Oc e l ll i n e ,
peripheral blood and microdissected tumor tissue was
amplified through quantitative methylation-specific
PCR (QMSP) [25]. Primers were designed according to
Figure 1 Toxicity profile of the 45 patients with severe toxicity treated with 5-FU according to Common Terminology Criteria for
Adverse Events, v4.0.
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sense strand of the DPYD gene, starting at -266 bp
from transcription start site (Genbank accession no.
NM_000110) as follows: forward, 5’-TTTGTTTGT
TTTCGATTCGC-3’; and reverse 5’-ATCCGCC-
GAATCCTTACTAA-3’ (amplicon size of 208 bp).
A reference gene (ACTB) was used to normalize for
DNA input in each sample[26]. Fluorescence based
QMSP assays were carried out using the SYBR® Green
PCR Master Mix (Applied Biosystems, USA). Running
conditions were: 50°C for 2 min, 95°C for 10 min fol-
lowed by 45 cycles of 95°C for 15 sec, and 60°C for
1 min. After 45 cycles, a dissociation-curve analysis
was performed using the following conditions: 95°C for
15 sec, 60°C for 20 sec and 95°C for 30 sec. Each sam-
p l ew a sr u ni nt r i p l i c a t ea n d , additionally, multiple
water blanks were used per plate as a control for con-
tamination (negative control). All amplifications were
carried out in 96-well plates on a 7500 Sequence
Detection System (Applied Biosystems, USA). In each
plate, five serial 10x-dilutions of fully methylated,
bisulfite converted DNA - CpGenome Universal
Methylated DNA [Millipore, CA, USA] - were also
included to construct the standard curve in order to
quantify the amount of fully methylated alleles in each
reaction. A run was considered valid when the follow-
ing six criteria were met: (1) slopes of each standard
curve above -3.60 corresponding to a PCR efficiency
>9 0 % ;( 2 )R
2 of at least four relevant data points
≥ 0.99; (3) no template controls not amplified; (4) the
positive methylation control had to provide a methy-
lated signal; (5) the negative control had no signal; and
(6) threshold cycle value for each gene ≤ 40. To deter-
mine the relative levels of methylated promoter DNA
in each sample, the values obtained by QMSP analysis
(mean quantity) for the target gene were divided by
the respective values of the internal reference gene
(ACTB). The ratio thus generated, which constitutes
an index of the percentage of input copies of DNA
that are fully methylated at the primer site, was then
multiplied by 1000 for easier tabulation (methylation
level = target gene/reference gene × 1000).
DPYD large genomic rearrangements analysis
Peripheral blood DNA samples were also screened for
DPYD large genomic rearrangements by Multiplex Ligation
Probe Amplification (MLPA) according to the manufac-
turer’s instructions (SALSA P103 kit; MRC, Holland). This
probemix contains probes with target-specific sequences
for each of the 23 exons and promoter region. Owing to
the large size of the introns, probes for five of the introns
are also included. The MLPA method is based on
sequence-specific probe hybridization to genomic DNA,
followed by PCR amplification of the hybridized probe
(with one FAM-labeled primer) and semi-quantitative ana-
lysis of the PCR products. A deletion or duplication was
scored if the relative peak area of the amplification product
presented a reduced or augmented area of 35 to 50% when
compared to a normal control, respectively. The kit also
contains a probe specific for the exon 14 skipping mutation
(IVS14+1G > A) that only generates a signal when the
mutation is present [27].
Statistical analysis
Descriptive statistics were used to summarize the clini-
copathological, molecular and immunoexpression data.
The independent samples Mann-Whitney U test was
applied to determine if the age distribution was the
same across genders. The analysis was performed with
PASW Statistics 18.0 software.
Results
No evidence of DPYD promoter methylation was
observed in any of the 45 peripheral blood samples nor
Table 2 Clinicopathological characteristics and toxicity profile of DPYD mutation carriers
Patient #1 Patient #2 Patient #3
Age 35 64 68
Gender female male female
Tumor
Location Colorectal Colorectal Esophageal
Type Adenocarcinoma Adenocarcinoma Squamous cell carcinoma
Stage IV IIIB IV
Treatment regimen
Toxicity profile
Mucositis G3 G4 G4
Anemia G4 G0 G0
Neutropenia G4 G4 G0
Thrombocytopenia G4 G0 G0
DPYD mutation type 1845 G > T IVS14+1G > A IVS14+1G > A
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patients experiencing severe 5-FU toxicity. Nevertheless,
DPYD promoter methylation was detected in the RKO
cell line (methylation ratio = 1075) (Figure 2).
Concerning mutation analysis, the MLPA assay was
performed in 42 of 45 cases (3 cases were not studied
due to low quality DNA). We were able to identify (Fig-
ure 3) the two exon 14 skipping mutation (IVS14+1G >
A) previously detected by direct sequencing analysis, but
not the 1845 G > T missense mutation. The remaining
39 patients with severe toxicity to 5-FU treatment that
did not carry clinically relevant allelic variants in exon
14 of DPYD, were further screened for large DPYD
intragenic rearrangements. No intragenic rearrange-
ments were found for DPYD in the peripheral blood
samples of those patients.
Figure 2 Illustrative QMSP amplification plots for 4 serial 10×-dilutions of fully methylated, bisulfite converted DNA (A, B, C, D) and
DPYD promoter methylation in RKO cell line (*). The DPYD/ACTB ratios were determined using the cycle number where fluorescence per
reaction crossed the threshold, which is set to the geometrical phase of polymerase chain reaction amplification above background. ΔRn is
defined as the cycle-to-cycle change in the fluorescence signal (log scale).
Figure 3 Capillary electrophoresis pattern of one normal control (green) and one case presenting the IVS14+1G > A mutation in the
DPYD gene (blue) detected by MLPA analysis. DPYD MLPA probe-mix presents a probe specific for the IVS14+1G > A mutation that will only
generate a signal when the mutation is present (arrow).
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5-FU is broadly used in the treatment of GI cancer.
Deficiency of the enzyme DPD, encoded by the DPYD
gene, has been associated with the development of
severe toxicity to 5-FU in GI cancer patients. Since
aberrant promoter methylation has been proposed as an
alternative mechanism of DPD deficiency, we assessed
the methylation status of DPYD promoter region by
quantitative methylation-specific PCR in GI cancer
patients who developed 5-FU-related severe toxicity.
Moreover, the analysis of large intragenic rearrange-
ments of DPYD, which have also been causally related
with DPD deficiency, was additionally performed.
Severe toxicity associated with 5-FU has been attribu-
ted in a small number of cases to allelic variants of the
DPYD gene, which result in lower DPD enzyme activity.
However, in most cases of severe 5-FU toxicity no
genetic mechanism has been described. Thus, a possible
role for epigenetic alteration of DPYD, especially promo-
ter methylation, has been hypothesized. The first pub-
lished study on this issue found that methylation of
DPYD promoter in peripheral blood leucocyte DNA
from colorectal patients was associated with severe 5-FU
toxicity[17]. In our series of 45 patients with GI cancer
with severe 5-FU toxicity, methylation at the DPYD pro-
moter was not found in any of the cases, neither in per-
ipheral blood leucocytes nor in tumor tissue samples.
Importantly, a well characterized colon cancer cell line
(RKO), known to harbor extensive CpG methylation at
the DPYD promoter, tested positive, thus validating the
methodology used in our study. Indeed, while this study
was being performed, two independent studies reported
similar findings in peripheral blood leucocytes of 28
patients[6] and 17 patients[28] with severe toxicity fol-
lowing 5-FU administration. It is noteworthy that the
first cited study examined only 15 individuals, of which
only five were cancer patients[17], whereas the two lat-
ter studies[6,28] and our own comprise a total of 90
patients, Indeed, our study has the largest single series
of patients among all cited studies. Thus, our data
further sustains that DPYD promoter methylation is
absent in patients treated with 5-FU for GI cancer
which have developed severe toxicity.
All patients enrolled in this study were screened for
DPYD exon 14 mutations by sequencing (including the
exon 14 skipping mutation IVS14+1G > A), eight of
which were included in a previous publication on unse-
lected colorectal cancer patients[29]. This mutation was
found in two patients (one previously reported) and
both of them developed severe toxicity following 5-FU
administration. Previous observations confirmed the
high specificity, positive and negative predictive values
of this genetic analysis[6,14,30]. However, our previous
analysis of 73 consecutive colorectal cancer patients
detected exon 14 mutations in only two of eight cases
with severe toxicity[29].
Both patients harboring the skipping mutation in exon
14 (IVS14+1G > A) and the patient harboring the 1845
G > T missense mutation, suffered from grade 4 toxicity
(mucositis and febril neutropenia) related to 5-FU che-
motherapy [29]. Thus, although DPYD mutational
screening identifies cases which are prone to develop 5-
FU-related toxicity, the low prevalence of those muta-
tions might raise questions regarding the cost-effective-
ness of the procedure.
Considering the results obtained for DPYD promoter
methylation and skipping mutation in exon 14 (IVS14+1G
> A) analysis, we decided to determine whether large
DPYD intragenic rearrangements might explain 5-FU
toxicity. However, those large intragenic rearrangements
were also not found in any of the 39 cases, thus excluding
a significant role for this genetic alteration in the impair-
ment of DPD activity. This result is also in agreement with
a recently published study in which no large rearrange-
ments were found in series of 68 patients experiencing
severe 5-FU toxicity[31,32].
In conclusion, considering our own and previously
published data, epigenetic silencing and intragenic rear-
rangements of DPYD do not contribute to the develop-
ment of severe 5-FU toxicity in GI cancer patients.
Although severe 5-FU toxicity is a significant clinical
concern, additional studies integrating a more compre-
hensive analysis of 5-FU metabolic pathway are required
to uncover the factors underlying the majority of
patients which experience severe 5-FU toxicity.
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